Key words
cranberry - dietary supplement interactions - kidney stone safety - warfarin - urinary
tract infection - Ericaceae
Abbreviations
AE:
adverse event
AER:
adverse event report
AHPA:
American Herbal Products Association
ANSES:
French Agency for Food, Environmental and Occupational Health & Safety
CAERS:
Center for Food Safety and Applied Nutrition Adverse Event Reporting System
CSR:
Cochrane systematic review
DAEN:
Database of Adverse Events Notifications
DS:
dietary supplements
DSHEA:
Dietary Supplement Health and Education Act
EFSA:
European Food Safety Authority
EMA:
European Medicines Agency
FDA:
U. S. Food and Drug Administration
GRAS:
generally recognized as safe
GRN:
generally recognized as safe notice
HDL:
high-density lipoprotein
INR:
international normalized ratio
LDL:
low-density lipoprotein
LNHPD:
Licensed Natural Health Products Database
MHRA:
Medicines and Healthcare Products Regulatory Agency
NDI:
New Dietary Ingredient
NDIN:
New Dietary Ingredient Notification
NHPID:
Natural Health Products Ingredients Database
NIH:
National Institutes of Health
PACs:
proanthocyanidins
TGA:
Therapeutic Goods Administration
USDA:
U. S. Department of Agriculture
USP:
U. S. Pharmacopeial Convention
UTI:
urinary tract infection
Introduction
Cranberry (Vaccinium macrocarpon Aiton) is a fruit native to North America [1], [2]. Cranberry was of importance to Native Americans in their diet, in commerce, and
for its medicinal properties [3]. Cranberry was used by Native Americans in a variety of foods, for dyeing rugs and
blankets, and for treating wounds [2].
There is a long history of scientific research on cranberry as an herbal remedy, dating
back to its chemical characterization in the late 19th century as described by Raz
et al. [4]. It was long believed that cranberries had medicinal properties related to the bladder
and kidneys due to urine acidification. German physicians determined that after the
ingestion of cranberries, urinary excretion of hippuric acid levels increased. Subsequent
research confirmed this phenomenon and attributed it to the benzoic acid found in
cranberries. The theory postulated that the benzoic acid was being converted into
hippuric acid in vivo and thus lowered the pH of urine. For a while after, researchers claimed that the
production of hippuric acid was enough to be considered bacteriostatic [4]. However, a 1959 article published by Bodel et al. [5] showed that cranberries were not a rich enough source of
benzoic acid for the resulting hippuric acid to be bacteriostatic.
The actual mechanism behind cranberriesʼ medicinal properties for the kidney and bladder
involve preventing microbial adhesion. This mechanism is attributed to PACs, specifically
proanthocyanidin-A found in cranberry, which exhibits potent in vitro anti-adhesion bioactivity [2], [6], [7], [8] and is thought to be responsible for interfering with bacterial adhesion to the
epithelial cells of the urinary tract [9]. This is why cranberry products are largely used today to prevent UTIs although
persuasive clinical evidence is still lacking [10].
Within the past 25 years, research on cranberry has progressed from its prevention
of UTIs to its effects on cardiovascular risk factors, metabolic syndrome, gut microbiota,
and cancer prevention [10]. Cranberry and its phytochemicals are suggested to have anticancer properties [11] and protective effects against vascular diseases [10]. The impact of cranberry on intestinal health has also been investigated, but most
data is from animal models and in vitro studies. While cranberry extract can alter the microbial composition in the gut of
mice, the effects of cranberry on gut microbiota in humans are unknown [10]. The Philip E. Marucci Center for Blueberry and Cranberry Research has a program
that conducts research on the health benefits of cranberry in the prevention and management
of bacterial diseases, including UTIs, stomach ulcers, and periodontal
disease [12].
In 2019, cranberry supplement products were the 5th best-selling supplements in U. S.
mainstream retail outlets ($ 88 900 064.38) and the 12th best-selling supplements
in U. S. natural and health food specialty retail outlets ($ 7 919 630.81 in total
sales) [13]. Given the popularity of cranberry as a dietary ingredient in DS, the USP has developed
quality standards for cranberry ingredients. USP is an independent, nonprofit, science-based
organization that sets public quality standards for medicines, foods, and DS. In setting
standards for DS, USP recognized that although manufacturers and suppliers of NDIs
may be required to submit an NDIN containing data on identity, manufacturing, toxicology,
and safety to the U. S. FDA before the DS can be legally introduced into the market,
there is no notification for many dietary ingredients, either because they were marketed
in DS before 1994 (pre-dating the DSHEA and are therefore not classified as
NDIs) or because they are NDIs for which a notification is not required under
the law (i.e., when the NDI and all other dietary ingredients in the DS have been
present in the food supply as articles used for food in a form in which the food has
not been chemically altered) [14]. Consequently, these ingredients may not have undergone a thorough safety evaluation.
In recognizing this gap, USP instituted the USP Dietary Supplements Admission Evaluation,
a process to evaluate articles for safety concerns before developing a monograph outlining
quality for a dietary supplement or dietary ingredient. The process includes a comprehensive
assessment of publicly available evidence conducted by the USP Dietary Supplements
Admission Evaluations Joint Standard Setting Subcommittee (DSAE JS3) to help ensure
that a dietary ingredient does not present serious health risk to public health [15]. This evaluation of cranberry ingredients was conducted according to USP guidelines
for the admission of DS ingredients into the monograph development process [16] and included an assessment to ascertain whether cranberry ingredients present a
severe risk to human health. This comprehensive review provided the data to determine
whether cranberry ingredients could be admitted to the USP monograph
development process. In this review, the safety of cranberry as a dietary ingredient
was assessed with a specific focus on kidney stone formation and drug-herbal interactions
with warfarin. Unless otherwise stated, throughout this article “cranberry” refers
to the cranberry fruit.
Literature Search Method
To find relevant safety information, the literature search focused on articles about
cranberry phytochemicals, clinical trials involving cranberry preparations or their
constituents, potential interactions of constituents, and studies on toxicology (in vitro and in vivo). Initial searches were conducted in PubMed by using the keywords “Cranberry”, “Cranberry
fruit”, or “Vaccinium macrocarpon”, combined with terms such as “safety”, “phytochemicals”, “clinical studies”, “adverse
events”, “drug interactions”, “animal studies”, and “in vitro” (earliest to 2020). During this review, kidney stone formation and interactions
with warfarin were identified as potential adverse effects of cranberry consumption;
therefore, an additional search was performed using the keywords described above and
the terms “kidney stone” and “warfarin interactions”. Additional electronic databases
that were used in the literature search included Google Scholar, TOXLINE,
ScienceDirect, and The Cochrane Library (earliest to 2020). Subsequent publications
were identified by searching the reference lists of relevant journal publications
and books. Additionally, texts about herbal ingredient safety were used in this review
for cranberry (e.g., AHPA Botanical Safety Handbook) [17].
Cranberry Phytochemistry and Pharmacopeial Quality
Cranberry Phytochemistry and Pharmacopeial Quality
Although they are composed of 88% water, cranberry is a rich source of phenolic compounds
such as PACs, anthocyanins, flavonoids, and phenolic acids [18], [19], [20]. PACs are polymeric condensation products of flavan-3-ols and are commonly consumed
flavonoids in the American diet [21]. The flavan-3-ols found in cranberry exist as monomers, oligomers, and polymers
[19]. The flavan-3-ol monomer and dimer content in cranberry is 70 – 330 µg/g, and the
anthocyanin content is 130 – 1710 µg/g [19]. However, the anthocyanin content can vary depending on the cultivar [2], [11], [19].
Cranberry contains both A-type and B-type PACs; however, the A-type PACs are present
in higher concentrations, accounting for 51 – 91% of total PACs [19]. The only structural difference between A-type and B-type PACs is that A-type have
an extra bond linking the top and bottom heterocycles. The structure of A-type and
B-type PACs is shown in [Fig. 1]. The average concentrations of PACs are 4.19 mg/g (0.4%) by weight in cranberry
and 231 mg/L in cranberry juice [2], [22]. Another publication reported a range of 1.33 – 3.67 mg/g of PACs in the fruit and
89 – 230 mg/L PACs in the juice [19]. Five laboratories performed analyses on 11 commercial powdered cranberry samples
and found that the PACs had a range of 0.63 – 177 mg/g [23]. The processing of cranberries into various products has been found to impact
PAC content [24], [25]. The total flavonol content in fresh cranberry is 0.2 – 0.4 mg/g [2], with approximately 75% of the flavonols being quercetin glycosides [11]. The quercetin content in cranberry varies from 0.11 – 0.25 mg/g. Myricetin and
kaempferol are the next most common flavonols [2]. Other cranberry constituents include triterpenoids, lectins, catechins, ascorbic
acid, benzoic acid, quinic acid, oxalic acid, citric acid, and malic acid [2], [19], [26].
Fig. 1 Structures of A-type (a) and B-type (b) proanthocyanidins (PACs).
Cranberry pomace is a byproduct of cranberry pressing and is composed of skin, seeds,
and stems [27], [28], [29]. Pomace is a rich source of polyphenolic compounds because the skins and seeds contain
high levels of these constituents [28], [29], [30]. Biochemical characterization of pomace extracts showed that they contain a broad
range of polyphenols that are also present in cranberry juice concentrates [30]. The crude content of polyphenols found in cranberry pomace is 6.0 mg/g [28]. The content of total anthocyanins, flavonols, and procyanidins reported in cranberry
pomace (per dry weight) is 1.214 mg/g, 3.584 mg/g, and 1.673 – 1.865 mg/g, respectively
[28], [29].
This review encompasses the following proposed USP monographs in development: Cranberry
Fruit Juice, Cranberry Fruit Juice Concentrate, Cranberry Fruit Juice Dry Extract,
and Cranberry Fruit Dry Juice. The proposed USP monographs define these ingredients
as derived from the fruits of Vaccinium macrocarpon Aiton (Ericaceae).
Cranberry fruit juice (formally cranberry liquid preparation) is defined as a bright
red juice having a content of soluble solids corresponding to a refractive index of
1.3435 – 1.3445 and containing no added substances. Cranberry fruit juice concentrate
consists of the bright red juice concentrated to a content of soluble solids corresponding
to a refractive index of 1.4191 – 1.4212. It contains not less than (NLT) 0.6% w/w
of total PACs, calculated as procyanidin A2 (C30H24O12), and contains no added substances. Cranberry fruit juice dry extract is prepared
from cranberry fruit juice concentrate after hydroalcoholic extraction over an adsorbent
resin. The extract contains NLT 15% of total PACs, calculated as procyanidin A2 on an as-is basis, and it may contain suitable added substances. Cranberry fruit
dry juice is obtained by drying cranberry fruit juice concentrate onto suitable carriers
and anticaking agents. It
contains no more than 50% suitable carriers and anti-caking agents. It contains
80 – 120% of the labeled amount of total PACs, calculated as procyanidin A2 on the dried basis. It also contains NLT 12% of total organic acids and 90 – 110%
of the labeled amount of total organic acids, both calculated as the sum of quinic
acid, malic acid, and citric acid on a dried basis. The ratio of quinic acid to malic
acid is NLT 1, and the ratio of quinic acid to citric acid is NLT 0.5.
This review also considers other cranberry preparations that are planned for USP monograph
development. These preparations include (1) cranberry fruit powder (whole berry, pulverized),
(2) cranberry pomace powder, and (3) cranberry pomace aqueous powder. The constituents
in cranberry fruit powder are the same as juice concentrate and dry juice in terms
of polyphenols, organic acids, and sugars. Cranberry pomace powder and cranberry pomace
aqueous powder are expected to contain much fewer polyphenols than cranberry juice
and cranberry fruit-derived ingredients and no sugar or organic acids.
Cranberry preparations can be adulterated by grape skin, hibiscus, blueberry, bilberry,
or peanut skin extracts [31]. One of the primary reasons for these substitutions is lower-cost sources of either
anthocyanins or PACs, including grapes (Vitis vinifera) and peanuts (Arachis hypogaea) [31]. Lower-cost anthocyanin-rich extracts include Mulberry (Morus spp.) fruit, hibiscus (Hibiscus sabdariffa), calyx, black bean (Phaseolus vulgaris) skin, or black rice (Oryza sativa) [31]. The proposed USP monographs for cranberry fruit juice, cranberry fruit juice concentrate,
cranberry fruit juice dry extract, and cranberry fruit dry juice include HPLC and
HTLC identification tests with anti-adulteration criteria to detect the possible presence
of other cyanidin sources such as hibiscus, blueberry, bilberry, or peanut skin extracts.
Regulatory Status of Cranberry and Reported Intake Levels
Regulatory Status of Cranberry and Reported Intake Levels
In the U. S., cranberry is available as an ingredient in numerous DS [32]. Cranberry powder and cranberry juice concentrate are included in the United Natural
Products Alliance list of old dietary ingredients [33]. Cranberry is also listed in the AHPAʼs Herbs of Commerce [34]. Although the FDA does not recognize these industry lists as authoritative, the
presence of cranberry on these lists suggests its use in DS on the market before the
enactment of DSHEA.
Cranberry extract was the subject of an NDIN (NDIN No. 902) that was submitted in
2015 to the FDA for a cranberry extract with A-type PACs [35]. The FDA objected to the NDIN because it included a drug claim for the prevention
of chronic and acute UTIs. Subsequently, the notifier submitted a new NDIN (NDIN No. 918)
with the drug claim removed, and the FDA expressed no further objections [36]. Information on the specifications and manufacturing method were redacted in the
publicly available NDINs, limiting its use for this review.
In 1999, a crospovidone-cranberry juice extract consisting of a cranberry extract
adsorbed to crospovidone was the subject of a GRN (GRN No. 30) submitted to the FDA.
The FDA concluded that the notice did not provide a sufficient basis for a GRAS determination
[37]. The FDA noted that GRN No. 30 did not have a comprehensive discussion of the published
scientific data, which did not follow the specific recommendations of the proposed
rule regarding the submission of a GRAS notice. Under the proposed rule (proposed
21 CFR 170.36[c][4][i][A]), a notifier would provide “a comprehensive discussion of,
and citations to, generally available and accepted scientific data, information, methods,
or principles that the notifier relies on to establish safety”. In addition, the notifier
stated that crospovidone is “declared GRAS” as a clarifying and stabilizing agent
in beverage processing, as listed in 21 CFR 173.50, to which the FDA responded that
the
assertion was incorrect, as the regulation is for a food additive and not for
a GRAS affirmation. The FDA noted the acute toxicity data provided for crospovidone-cranberry
juice extract was insufficient to support its safety for the amount of crospovidone
that would be consumed. The FDA also noted that cranberry contains a significant amount
of mutagenic phenolic compounds, including quercetin (73 – 250 mg/kg fresh weight),
myricetin (4.0 – 26.7 mg/kg), and kaempferol (0 – 2.7 mg/kg). Quercetin, myricetin,
and kaempferol were demonstrated to be mutagenic by the Ames test, and the National
Toxicology Program presented evidence of carcinogenic activity (i.e., increased incidence
of renal tubule cell adenomas) of quercetin in male F344/N rats [38]. The FDA remarked that GRN No. 30 did not address or contradict these findings [37]. However, the International Agency for Research on Cancer (IARC) has evaluated quercetin,
which included a review of the NTP study in F344/N rats along with other available
animal and human data, and the IARC concluded that there is limited evidence in experimental
animals and inadequate evidence in humans for the carcinogenicity of quercetin. The
IARC classified quercetin as Group 3: not classifiable as to its carcinogenicity to
humans [39]. In 2020, cranberry extract powder was the subject of GRN No. 873 that was submitted
to the FDA. The cranberry extract powder was specified for intended use in beverages,
beverage bases, ready-to-drink coffee drinks at a level of 150 mg/8 oz serving (62.5 mg/100 g),
and processed fruits and fruit juices at a level of 300 mg/8 oz serving (125 mg/100 g).
The FDA had no questions and filed GRN No. 873 in May 2020 [40].
In July 2020, the FDA announced that it does not intend to object to the use of certain
qualified health claims regarding the use of certain cranberry juice beverages and
cranberry powder supplements and a reduced risk of recurrent UTI in healthy women
[41]. In response to a petition to authorize a health claim regarding the relationship
between the consumption of cranberry products and a reduced risk of recurrent UTI
in healthy women, the FDA found limited and inconsistent credible scientific evidence
to support an authorized claim. As a result, the petitioner agreed to have the petition
evaluated as a qualified health claim petition. As described in the FDAʼs enforcement
discretion letter, the agency does not intend to object to specified claims regarding
consumption of cranberry juice beverages (8 oz.) containing at least 27% cranberry
juice and cranberry DS containing at least 500 mg of cranberry powder (100% fruit)
and a reduced risk of
recurrent UTI in healthy women. The claims specified by FDA include qualifiers
about the level of scientific evidence on the reduced risk of recurrent UTI in healthy
women. For the qualified health claims, cranberry juice beverages have the qualifier
“limited and inconsistent scientific evidence” and cranberry DS has the qualifier
“limited scientific evidence”. The qualified health claims do not include other conventional
foods or food products made from or containing cranberries (e.g., dried cranberries
or cranberry sauce).
Regulatory listings were found for the cranberry in other countries. In Canada, cranberry
is recognized as a natural health product [42]. Health Canadaʼs NHPID lists cranberry and dried cranberry juice as a Schedule 1
plant and Item 1 plant material under the natural health product regulations. For
cranberry, the proper name listed in NHIPD is Vaccinium macrocarpon, and listed common names are American cranberry, cranberry, large American cranberry,
and large cranberry [42]. Health Canada has monographs for cranberry and dried cranberry juice [43], [44]. A total of 384 active licensed products containing cranberry were listed in Canadaʼs
LNHPD [45]. In 2017, the EFSA evaluated the safety of cranberry extract powder as a novel food
ingredient under Regulation (EC) No 258/97 [46]. In March 2011,
ANSES published an opinion on the potential effects of cranberry on community-acquired
UTIs, which included a safety evaluation on cranberry juice and cranberry products
[47]. In December 2020, the European Scientific Cooperative on Phytotherapy (ESCOP) published
a monograph on cranberry [48]. A total of 97 approved single medicine products containing cranberry are listed
in the Australian Register of Therapeutic Goods [49].
Data were searched to determine the daily intake levels of cranberry ingredients in
DS on the market. Using the search term “cranberry” for product labels in the NIH
Dietary Supplements Label Database (DSLD), as of September 11, 2019, up to 1817 products
containing cranberry as an ingredient were listed [50]. Products that listed the amount of cranberry on the label had daily serving sizes
that ranged from 2 to 2000 mg, and 1 product had a daily serving size as low as 50 µg
of cranberry. The products contained different preparations of cranberry such as cranberry
powder, cranberry concentrate, or cranberry extract. The DS manufacturersʼ recommended
daily intakes ranged from 4 to 5580 mg of cranberry powder, 10 to 1350 mg of cranberry
extract, and 10 to 1500 mg of cranberry concentrate. DS products containing cranberry
had either single or multiple ingredients, and most are sold as either capsules or
tablets.
In NDIN No. 918, the recommended daily intake of cranberry extract (containing 36%
PACs) as a DS is 120 mg of cranberry extract powder or 1 mL of cranberry extract liquid,
twice daily, providing a maximum daily intake of 240 mg or 2 mL, respectively (i.e.,
1 mL of liquid contains 120 mg of cranberry extract) [36]. The maximum intake of PACs from either cranberry extract powder or liquid is 86.4 mg/day.
Intake levels of cranberry extracts for use in foods have been described in GRN No. 873
[40] and the EFSA Journal [46]. In GRN No. 873, the mean and 90th percentile estimated daily intakes for cranberry
extract powder (containing approximately 55% PACs) from proposed food uses were described
as 332 and 639 mg/day, respectively. These intakes of extract provide 182.6 and 351.5 mg/day
of PACs, respectively [40]. The EFSA assessment of cranberry extract powder
(containing 55 – 60% PACs) as a novel food reported that for the proposed uses
in yogurts and beverages, the 95th percentile estimated daily intakes were 319 mg/day
in women and 366 mg/day in men. These intake levels of cranberry extract provide 192
and 219 mg/day PACs in women and men, respectively [46].
Health Canada monographs for cranberry and dried cranberry juice recommend intake
levels of 10 – 30 g/day of fresh fruit, 90 – 950 mL/day of fruit juice, and 400 – 1200 mg/day
of dried fruit juice when used as a source of antioxidants [43], [44]. The American Botanical Councilʼs Herbalgram Cranberry monograph reported intakes of 300 to 400 mg of concentrated cranberry juice
extract 2 to 3 times daily are recommended for the treatment and prevention of UTIs
[51]. An intake of 300 mL/day of cranberry juice cocktail containing 36 mg/day of PACs
is recommended for the prevention of UTIs [24].
Clinical Evidence of Safety
Clinical Evidence of Safety
The efficacy of cranberry preparations in the prevention of UTIs has been investigated
in numerous clinical studies [20], [24]. A 2012 CSR was conducted for cranberry clinical studies for UTI prevention [24]. The review assessed 24 clinical studies with a total of 4473 participants (updated
from the last 2008 CSR) and included 6 cross-over studies, 11 parallel-group studies
with 2 arms, 5 studies with 3 arms, and 2 with a factorial design. The studies evaluated
cranberry juice cocktails or concentrates (30 to 1000 mL/day) or cranberry tablets
or capsules (400 to 2000 mg/day). The CSR reported no significant difference between
gastrointestinal (GI) adverse effects for groups treated with cranberry products compared
to the placebo or no-treatment control groups (RR 0.83, 95% CI 0.31 to 2.27). Low
compliance and high withdrawals reported in the clinical studies were attributed to
the
palatability or intolerance of the cranberry products, primarily for cranberry
juice when taken over long periods [24]. Five studies reported no withdrawals, but the withdrawal rate reported in the other
studies varied considerably, from 3 to 55%. Two of the studies were conducted in pregnant
women using high intake levels of cranberry juice (up to 1000 mL/day) and had withdrawals
of 28% and 39% [24]. In one of the studies, the withdrawal of 73 out of 188 participants was mainly
due to GI upset including nausea, vomiting, diarrhea, and palatability issues. Therefore,
the intake level of cranberry juice was reduced from 720 mL to 540 mL daily (240 mL
taken 3 times daily, then reduced to 2 times daily) [52]. In the other study [53], the high withdrawal of 122 out of 380 participants was attributed to GI upset in
pregnant women when given 250 mL cranberry juice 4
times daily (1000 mL daily) [53], [54]. Another study, with a withdrawal rate of 55%, was conducted in elderly participants
(n = 38; mean age 81 y) who were given 30 mL cranberry juice mixed with water for
up to 4 wk. The concentration of juice and PAC content were not provided. The study
was a cross-over design in which the control group was given the same volume of water
[55]. Insufficient details were available to ascertain why this study had a high withdrawal
rate for a low cranberry juice intake [24].
The CSR noted that many clinical studies were low quality and suggested that the use
of encapsulated cranberry preparations may prevent the low compliance that was observed
for cranberry juice [24]. However, most of the studies that used cranberry tablets or capsules did not report
on the content of the active ingredients. Furthermore, PAC levels in the cranberry
products were mostly unreported in the clinical studies [24]. AEs were not well reported across the clinical studies, and only 7 studies stated
the number of AEs within each study arm. The AEs were mild, similarly distributed
across treatment arms, and mainly GI-related adverse effects [24]. Another meta-analysis was comprised of 13 clinical trials examining the efficacy
of cranberry products in preventing UTIs in 1616 mostly female patients (8 studies
with juice or concentrate, 4 studies with tablets or capsules, and 1 study
with both). While the authors did not discuss AEs or compliance rates in their
analysis, they did note that the use of cranberry juice in clinical studies was associated
with compliance issues [56].
A randomized clinical study published in 2012 evaluated the effects of consuming cranberry
juice for 6 mo in women with a history of UTIs (n = 176) [57]. Women were given either 4 oz of cranberry juice once daily (n = 60), 8 oz of cranberry
juice once daily (n = 60), or a placebo juice (n = 56). The juice contained 27% cranberry
juice and sucralose and was similar in composition to commercially available low-calorie
cranberry juice. The PAC levels in the cranberry juice were not reported. Adverse
effects were assessed at monthly visits, and no serious AEs were reported. Minor adverse
effects included primarily GI (constipation, heartburn, loose stool), vaginal (itching,
dryness), and migraine symptoms. The proportions of women who reported minor adverse
effects were 29 of 120 participants (24.2%) in the cranberry juice groups and 7 of
56 participants (12.5%) in the placebo group (p = 0.07). Three women in the cranberry
treatment groups (1 woman
given 4 oz of cranberry juice and 2 women given 8 oz of cranberry juice) stopped
taking the cranberry juice because of GI symptoms thought to be related to the product.
The authors noted that the tolerability of cranberry juice products has been problematic
in clinical studies. However, the authors noted that participants in their study had
higher adherence to daily intakes than individuals in previous studies. Therefore,
the use of cranberry solids in products may be a more viable option for continuous
daily intakes [57].
Other clinical studies not assessed in the CSR have evaluated cranberry extracts and
their effects on UTI prevention. Three clinical studies published between 2015 and
2017 evaluated the efficacy of a standardized cranberry extract product in the following
individuals with a history of recurrent UTIs: juveniles between 12 and 18 y of age
[58], adult females [59], and elderly men suffering from moderate prostatic hyperplasia [60]. The participants were given 1 daily capsule containing 120 mg of cranberry extract,
standardized to 36 mg PACs, for up to 60 days. The authors reported that no AEs were
observed in these studies, although the monitoring of AEs was not described, and no
other clinical safety parameters were mentioned. All of the studies reported high
compliance for the cranberry extract (> 91% in juveniles and > 95% in adult women
and elderly men) [58], [59], [60].
One randomized placebo-controlled clinical study published in 2016 evaluated the efficacy
of a standardized proanthocyanidin-A cranberry extract in patients with recurrent
UTIs [61]. Patients were given one 60 mg capsule of standardized proanthocyanidin A cranberry
extract twice daily (n = 36) or a placebo (n = 36) for 12 wk. The concentration of
proanthocyanidin A in the cranberry extract was not specified. The participants were
assessed for side effects, AEs, and compliance, but no other clinical safety parameters
were mentioned. The authors reported no AEs except for constipation in 1 subject in
each group, and there were no withdrawals from the study. The authors concluded that
the cranberry extract was well tolerated and shown to significantly lower the number
of UTI episodes (p < 0.001).
A double-blind, randomized, placebo-controlled efficacy study evaluated cranberry
capsules on bacteriuria plus pyuria among older women in nursing homes [62]. The study was conducted from 2012 to 2015 in female nursing home residents (n = 185).
Participants (n = 92) were given 2 cranberry capsules daily, with each capsule containing
36 mg of PAC (i.e., 72 mg PAC daily, equivalent to 20 ounces of cranberry juice) or
a placebo (n = 93). Adherence was determined by the number of capsules administered
to each subject (high adherence was defined as ≥ 80%), and AEs were recorded and reviewed
monthly. No other clinical safety parameters were described. During the study, 3830
AEs were reported, of which 116 were serious (83 hospitalizations and 33 deaths, all
protocol-unrelated and anticipated) and 3714 were nonserious (14 protocol-related
and anticipated). The authors reported that the nature and frequency of the 14 protocol-related
and anticipated
nonserious AEs–altered mental status, GI disturbance, oral cavity disturbance,
skin and soft tissue events, and weight loss–were similar between the cranberry treatment
and placebo groups.
One clinical study included healthy women who were given dried cranberry juice for
8 wk (n = 65) [63]. Women were given either placebo, 400, or 1200 mg/day of dried cranberry juice (n = 23,
20, and 22, respectively). The dried cranberry juice contained 3% total polyphenolic
content, 0.3% quercetin, and 0.44% anthocyanin pigments, along with 1 – 10% phenolic
acids (w/w). The authors estimated that 1200 mg/day of dried cranberry juice provided
a daily intake of 35 mg of total phenols, 7.8 mg of anthocyanins, and 14.4 mg of PACs.
Biochemical parameters (cholesterol, HDL cholesterol, LDL cholesterol, triacylglycerols,
alanine transaminase, aspartate aminotransferase, gamma-glutamyltransferase, urea,
creatinine, uric acid, and advanced oxidation protein products levels in serum) and
hematological parameters (blood count, including a differential leukocyte count) were
assessed. The authors reported that 57 out of 65 participants completed the study.
Two women given the placebo withdrew, due to either respiratory illness (1) or
personal reasons (1). Six women given 1200 mg/day of dried cranberry juice withdrew,
due to respiratory disease (2), excessive urination (1), stomach acidity (1), or personal
reasons (1). However, the authors did not report the cause of the sixth withdrawal,
or possibly only 5 women withdrew. No withdrawals were reported for the group given
400 mg/day of dried cranberry juice. No adverse effects on biochemical and hematological
parameters were reported for either treatment group, and values were within the normal
physiological range. The authors concluded that an intake of 1200 mg/day of dried
cranberry juice was effective for preventing UTIs but did not discuss its safety.
[Table 1] summarizes the key safety outcomes of each clinical study including a description
of AEs and study withdrawals.
Table 1 Summary of clinical trials on cranberry preparations and safety outcomes.
|
First author [Reference]
|
Study type
|
Patient characteristics (treated/control)
|
Cranberry preparation
|
Intervention/duration
|
Adverse events
|
Withdrawals/reason
|
|
Wing [52]
|
Randomized, placebo-controlled
|
Pregnant women: n = 188 (67/58/63)
|
27% cranberry juice
|
Cranberry: 1 × 240 mL daily; 3 × 240 mL daily (reduced to 2 × 240 mL daily to improve
tolerability)
Placebo: 3 × 240 mL (placebo drink); Duration: until delivery
|
GI upset (nausea, vomiting, diarrhea, dislike of taste)
|
73/188 (39%)/mainly GI upset related to cranberry product
|
|
Essadi [53]
|
Randomized, placebo-controlled
|
Pregnant women: n = 760 (380/380)
|
Cranberry juice (no description)
|
Cranberry: 4 × 250 mL daily
Placebo: 4 × 250 mL daily (water)
Duration: not specified
|
GI upset (no further description)
|
122/380 (32%)/mainly GI upset related to cranberry product
|
|
Haverkorn [55]
|
Cross-over with placebo
|
Elderly men and women: n = 38 (38/38)
|
Cranberry juice (no description)
|
Cranberry: 2 × 15 mL daily (juice mixed water
Placebo: 2 × 15 mL daily (water)
Duration: 4 weeks
|
Not reported
|
21/38 (55%)/no reason provided
|
|
Stapleton [57]
|
Randomized, placebo-controlled
|
Adult women with history of UTIs: n = 176 (60/60/56)
|
27% cranberry juice
|
Cranberry: 4 oz once daily; 8 oz once daily
Placebo: matching placebo juice (volume not specified)
Duration: 6 months
|
GI upset (constipation, heartburn, loose stool), vaginal (itching, dryness), migraine
symptoms
|
3/120 (2.5%)/GI upset related to cranberry product
|
|
Ledda [58]
|
Pilot with control
|
Juveniles with history of UTIs: n = 36 (19/17)
|
Cranberry extract (standardized to 36 mg PACs)
|
Cranberry: 120 mg daily (capsule)
Control: standard management Duration: 60 days
|
None observed
|
None observed/> 91% compliance for cranberry product
|
|
Ledda [59]
|
Pilot with control
|
Women with history of UTIs: n = 44 (22/22)
|
Cranberry extract (standardized to 36 mg PACs)
|
Cranberry: 120 mg daily
Control: standard management
Duration: 60 days
|
None observed
|
None observed/> 95% compliance for cranberry product
|
|
Ledda [60]
|
Pilot with control
|
Elderly men with history of UTIs: n = 43 (23/21)
|
Cranberry extract (standardized to 36 mg PACs)
|
Cranberry: 120 mg daily
Control: standard management
Duration: 60 days
|
None observed
|
None observed/> 95% compliance for cranberry product
|
|
Singh [61]
|
Randomized, placebo-controlled
|
Adults with recurrent UTIs: n = 72 (36/36)
|
Cranberry extract (standardized to 36 mg PACs)
|
Cranberry: 2 × 60 mg capsule daily
Placebo: 2 × Lactobacillus acidophilus capsules daily
Duration: 12 weeks
|
Constipation
|
None observed/% compliance not reported
|
|
Juthani-Mehta [62]
|
Randomized, placebo-controlled
|
Elderly women in nursing homes: n = 185 (92/93)
|
Cranberry (standardized to 36 mg PACs)
|
Cranberry: 2 cranberry capsules daily
Placebo: 2 placebo capsules daily Duration: 360 days
|
Altered mental status, GI disturbance, oral cavity disturbance, skin and soft tissue
events
|
Not reported/% compliance not reported
|
|
Valentova [63]
|
Double-blind placebo-controlled
|
Healthy women: n = 65 (20, 22, 23)
|
Dried cranberry juice (equivalent to 5 g fresh cranberry)
|
Cranberry: 2 × 200 mg capsules daily; 3 × 200 mg capsules daily
Placebo: 2 × placebo capsules daily
Duration: 8 weeks
|
Respiratory disease, excessive urination, stomach acidity
|
7/65 (10.8%)/due to respiratory disease, excessive urination, stomach acidity, or
personal reasons
|
Animal Toxicology, In Vitro Studies, and Pharmacokinetics
Animal Toxicology, In Vitro Studies, and Pharmacokinetics
An oral LD50 of > 5 g/kg was established for a cranberry powder standardized to 1.5% PACs when
administered to female Sprague Dawley rats in an acute study following Economic Cooperation
and Development (OECD) guidelines [64]. Single oral doses up to 5600 mg/kg of cranberry ethanolic extract showed no lethality
in CD-1 male mice [65]. No other details were reported for these acute studies.
A 14-wk study was conducted in male Wistar rats (n = 6 per 3 experimental groups and
a placebo group), where the experimental groups were each given a different commercial
cranberry powder product in their diet at a concentration of 1500 mg of cranberry
product/kg of feed (1500 ppm) [66]. The treated rats were exposed to up to 0.60 mg/kg/day of PACs [46]. The cranberry products were well tolerated and did not affect hematology parameters,
body weight, or food consumption. Plasma alkaline phosphatase was significantly decreased
in one of the experimental groups (p < 0.05), but the authors did not mention if this
change was adverse. No effects on organ weights, gross pathology, or histopathology
were observed, and total cytochrome P450 levels in the liver were not affected by
the treatment with the cranberry products [66]. The authors reported the daily dose of cranberry powder
administered to rats that was 10 times higher than the intake level used in one
clinical study in healthy women [63]. The clinical study used an intake level of 1200 mg/day of dried cranberry juice
and accordingly the human dose was approximately 17 mg/kg/day (1200 mg/day ÷ 70 kg
body weight). Therefore, the estimated dose of cranberry powder fed in rats was 170 mg/kg/day
in which no toxicity was observed, indicating that commercial cranberry powder is
safe in humans at an intake level that is 10 times lower than in rats.
One study evaluated cranberry extract powderʼs effect in dogs (schnauzers and Chihuahuas)
with a history of recurrent UTIs [67]. The dogs (n = 6 per group) were given either 20 mg/kg cephalexin or cranberry extract
powder (1 g for dogs < 25 kg and 2 g for dogs ≥ 25 kg) for 6 mo. Monthly physical
examinations, hematologic examinations, biochemical analysis, and urinalysis were
performed. No adverse effects attributable to cranberry extract powder were reported
by the authors, although no data were provided in the publication and the study was
not designed to evaluate toxicity.
No reproductive or developmental toxicity studies were identified for cranberry ingredients.
Three commercial cranberry products containing low phenolic concentrations were not
genotoxic in peripheral lymphocytes of treated male Wistar rats when analyzed by the
Comet assay [66]. No genotoxicity was observed in a micronucleus test conducted in CD-1 male mice
orally administered 800 mg/kg/day of cranberry ethanolic extract for 1 wk [65]. No Ames or in vitro micronucleus tests and no chronic or carcinogenicity studies were available for cranberry
ingredients. [Table 2] summarizes the key safety outcomes of each preclinical study including a description
of any adverse effects.
Table 2 Summary of preclinical studies on cranberry preparations and safety outcomes.
|
First Author [Reference]
|
Study Type
|
Species/strain
|
Cranberry Preparation
|
Intervention/Duration
|
Adverse Effects
|
Safety Outcome
|
|
Sengupta [64]
|
Oral acute (OECD guideline)
|
Female rats/Sprague Dawley
|
Cranberry extract (standardized to 1.5% PACs)
|
Cranberry: individual dose levels not reported
Placebo: not reported
Duration: single dose
|
Not reported
|
Oral LD50 of > 5 g/kg
|
|
Madrigal-Santillán [65]
|
Oral acute (no guideline reported)
|
Male mice/CD-1
|
Cranberry ethanolic extract (12.6% yield)
|
Cranberry: 10, 100, 1000, 1600, 2900, 4300, 5600 mg/kg
Control: not reported
Duration: single dose
|
Not reported
|
No lethality up to 5600 mg/kg
|
|
Palikova [66]
|
Dietary (no guidance reported)
|
Male rats/Wistar
|
3 commercial cranberry powders
|
Cranberry: 1500 ppm in diet (estimated dose of 170 mg/kg/day)
Placebo: stock diet
Duration: 14 weeks
|
Plasma alkaline phosphatase significantly decreased in one cranberry group (p < 0.05),
but it was not mentioned if this change was adverse
|
Reported as well-tolerated
|
|
Chou [67]
|
Oral repeat-dose (no guidance reported)
|
dogs/schnauzers and Chihuahuas with a history of recurrent UTIs
|
Cranberry extract powder
|
Cranberry: 1 g for dogs < 25 kg and 2 g for dogs ≥ 25 kg (mixed with food)
Control: 20 mg/kg cephalexin Duration: 6 months
|
None observed
|
No adverse effects attributable to treatment was reported
|
|
Palikova [66]
|
Dietary (no guidance reported) – Comet assay
|
Male rats/Wistar
|
3 commercial cranberry powders
|
Cranberry: 1500 ppm in diet (estimated dose of 170 mg/kg/day)
Placebo: stock diet
Duration: 14 weeks
|
None observed
|
Not genotoxic in peripheral lymphocytes of treated rats
|
|
Madrigal-Santillán [65]
|
Oral micronucleus test
|
Male mice/CD-1
|
Cranberry ethanolic extract (12.6% yield)
|
Cranberry: 800 mg/kg/day
Control: negative (without treatment)
Duration: 1 week
|
None observed
|
Not genotoxic in erythrocytes of treated mice
|
Limited pharmacokinetic studies were available for cranberry ingredients. Male Wistar
rats administered 3 commercial cranberry powder products at 1500 ppm in the diet for
14 wk showed significantly higher concentrations of phenolic acids in their plasma,
urine, feces, and liver compared to control rats [66]. Levels of anthocyanins in plasma, feces, urine, and liver were under the limit
of quantification (< 10 µg/mL), which may be explained by their conversion into hippuric
acid. Hippuric acid was significantly elevated in the urine of treated rats, and it
appears to be the main metabolite of phenolic acids, benzoic acid, flavonoids, anthocyanins,
and probably PACs. The urine concentration of hippuric acid corresponded well with
intakes of phenolics [66].
The absorption of PACs is low, and only PACs with a low degree of polymerization (i.e.,
dimers) can be absorbed. Oligomeric and polymeric PACs are proposed to be transported
to the large intestine and broken down into simple phenolic acids by microbiota and
are subsequently absorbed. PAC polymers could be degraded into monomers under the
acidic conditions of the stomach based on in vitro studies, although this may not occur readily in humans [46].
AEs Associated with Cranberry
AEs Associated with Cranberry
In the clinical studies reviewed herein, no serious AEs were reported for cranberry.
The most common AEs observed for cranberry involved the GI tract. GI symptoms such
as diarrhea may result from high intakes (more than 3 to 4 L daily) of cranberry juice
[51], [56]. GI distress, including diarrhea, was reported in infants and children consuming
more than 3 L daily of cranberry juice [26]. The 2011 published opinion by ANSES on the potential effects of cranberry on community-acquired
UTIs included a safety evaluation on cranberry juice and cranberry products, and it
noted that side effects were predominantly GI-related (gastroesophageal reflux, nausea,
and digestive disorders) and mostly observed for large intakes of cranberry juice
or beverage over prolonged periods. ANSES concluded that “there is no safety concern
related to the consumption of cranberry by the general population. Adverse
effects are mainly digestive and usually occur after high consumption of cranberry
over the long term, particularly as a beverage” [47].
The AHPA Botanical Safety Handbook classifies cranberry as Safety Class I (i.e., an
herb that can be safely consumed when used appropriately) [17]. One published review assessing cranberry in the prevention of UTIs reported that
besides issues with palatability, there are no safety concerns [17], [68]. Nevertheless, some potentially serious AEs have been reported in case reports describing
the use of cranberry. These include kidney stone formation and herbal-drug interactions,
specifically with the anticoagulant drug warfarin. The case reports and the available
studies associated with cranberry are described below.
A search using the term “cranberry” was conducted of the publicly available FDA CAERS
database. The results included 292 AE reports (AERs) [69]. The majority of the AERs were related to cranberry juice products; however, AERs
were also related to other cranberry preparations, including tablets, caplets, soft
gels, pills, and extracts. Some AERs did not include the specific type of cranberry
product. Causality assignment was not possible, in part, because the majority of these
AERs involved multi-ingredient products and/or the concomitant intake of other supplement
products.
The Canada Vigilance Program database was searched using the following keywords: “cranberry”,
“cranberry extract”, “cranberry juice powder”, “dried cranberry extract”, and “dried
cranberry juice”. The search yielded a total of 43 AERs related to cranberry products
[70]. Two AERs for cranberry juice products described decreased prothrombin levels or
a prolonged prothrombin time. Both involved the use of the drug warfarin/Coumadin.
Additionally, both AERs involved the simultaneous intake of other medications. Another
AER for cranberry tablet described an increased INR but involved the simultaneous
intake of a prescription blood thinner/anticoagulant and other herbal products. The
AERs included varied symptoms with no specific target organ system, and they involved
multi-ingredient products and/or the concomitant intake of multiple health products
or medications. Due to these factors, a causality assignment was not possible.
A total of 28 AERs associated with cranberry were listed in the Australian TGA DAEN
[71]. Of the 4 AERs involving the use of a cranberry product and the medication warfarin,
3 described an increase in the INR and 1 included an abnormal coagulation test. Three
of the AERs involved the concomitant intake of other supplement products or medicines.
The AER that involved the intake of only 1 cranberry product with warfarin did not
include the cranberry product ingredients. However, a follow-up internet search of
commercially available products showed it contained dried cranberry juice (equivalent
to 10 g of fresh fruit) and 100 mg of vitamin C (ascorbic acid). Because this AER
was reported in 2004, it is uncertain whether the product formulation contained the
same content or ingredients that are currently available. Overall, a causality assignment
was not possible, in part, because the AERs involved multi-ingredient products and/or
the concomitant
intake of other supplement products or medicines.
No AERs were listed for cranberry in the following databases: British MHRA Yellow
Card database [72], the EudraVigilance European database [73], and New Zealandʼs MedSafe [74].
Kidney Stone Formation and Cranberry
Kidney Stone Formation and Cranberry
Human clinical studies have reported contradictory data about cranberry and its role
in kidney stone formation [17]. Some studies indicated that individuals with a history of developing uric acid
or calcium oxalate stones are at risk when consuming cranberry products [75]. In contrast, other studies have reported that consumption of large amounts of cranberry
may reduce kidney stone formation or urinary ionized calcium associated with stone
formation [51], [76], [77]. One case report of kidney stone formation associated with the intake of a DS containing
cranberry was identified. A 47-year-old man with a history of kidney stones presented
with right renal colic and hematuria and a creatinine level of 2.1 mg/dL. Abdominal
films revealed multiple kidney stones and distal ureteral and mid ureteral stones.
The patient had taken
cranberry concentrate tablets twice daily for the previous 6 mo and had no kidney
stones 1 year before the AE. The kidney stones in the patient were determined to consist
of calcium oxalate. It was not reported if the patient was taking other supplements
or medications at the time. The authors did not report the level of cranberry concentrate
in the tablets taken by the patient. However, they mentioned that several brands of
cranberry concentrate tablets are commercially available and the product label for
one commercially available 450 mg tablet of cranberry concentrate (equivalent to 2880 mL
of cranberry concentrate juice) includes the recommendation to take the tablet twice
daily [75].
Based on this case report described above, a clinical study was conducted to further
investigate the link between kidney stone formation and cranberry concentrate tablets.
The study reported a significant increase in urinary oxalate levels in healthy participants
given cranberry concentrate tablets for 1 wk (n = 5) [75], prompting caution that individuals with existing nephrolithiasis might be at increased
risk of kidney stone formation when consuming large amounts of cranberry [26], [78]. The study also reported a significant increase in urinary calcium, phosphate, and
sodium, along with magnesium and potassium, which are both inhibitors of stone formation.
The authors proposed that the oxalate content in cranberry could cause kidney stone
formation; however, the authors did not measure oxalate levels in the cranberry tablets.
The authors noted there is one report that a 30 mL volume of
cranberry juice contains approximately 1.89 mg of oxalate. Although the oxalate
content in the tablets was not reported, the authors estimated that if the oxalate
content was proportional to the volume of cranberry juice in the tablets, then the
twice-daily dosing with cranberry tablets containing 450 mg of cranberry concentrate
would contain approximately 363 mg of oxalate per day [75]. Notably, the clinical study was criticized for not measuring the content of oxalate
in the cranberry concentrate tablets and for not assessing dietary intakes of vitamin
C or calcium in the participants, both of which can contribute to urinary oxalates
[79].
Other studies have reported contradictory findings regarding the role of cranberry
in kidney stone formation, and the risk may depend on the different types of stone
formation (i.e., calcium oxalate versus apatite, brushite, and struvite stone formation). A systematic review and meta-analysis
reported that insufficient data were available to link cranberry juice to the risk
of kidney stones, although some studies have reported that various juices, including
cranberry juice, are associated with reducing the risk of kidney stones [80]. One clinical study reported that 500 mL of cranberry juice given to healthy men
for 2 wk had shown favorable effects on risk factors for stone formation (n = 20),
which included a decrease in oxalate and phosphate excretion, an increase in citrate
excretion, and a decrease in relative supersaturation of calcium oxalate [76]. The authors noted that participants given cranberry
juice had significantly higher dietary intakes of oxalate and ascorbic acid (p = 0.0184
and < 0.001, respectively), which were attributed to the content of oxalate and ascorbic
acid measured in the cranberry juice (86 mg/mL and 300 mg/L, respectively) compared
to control participants given water. The authors concluded that cranberry juice shows
antilithogenic properties [76]; however, the intake of oxalate from the cranberry juice (43 mg/day) used in this
study was an order of magnitude lower than the estimated intake of oxalate (363 mg/day)
in the clinical study [75] that evaluated cranberry concentrate tablets.
A 7-day clinical study evaluated the effects of consuming 1 L of cranberry juice daily
in healthy individuals and those with a history of forming calcium oxalate stones
(n = 12 per group) [81]. Cranberry juice significantly increased urinary calcium and urinary oxalate levels,
thereby increasing urinary saturation of calcium oxalate by 18% across treatment groups.
However, urinary citrate was unchanged; urinary magnesium increased slightly; and
urinary ammonium, titratable acidity, and net acid excretion increased. Urinary and
serum uric acid also decreased, which the authors mentioned could offset the propensity
of uric acid crystallization associated with a lower urinary pH. The authors concluded
that cranberry juice exerts a mixed impact on the crystallization of kidney-stone-forming
salts: while crystallization of calcium oxalate was enhanced, brushite and monosodium
urate saturation were reduced. Overall, cranberry juice may not
substantially affect kidney stone formation.
In another study, healthy male participants given 330 mL of cranberry juice daily
for 5 days had decreased urinary pH and increased excretion of oxalic acid and relative
supersaturation of uric acid (n = 12). Excretions of citric acid, calcium, magnesium,
and uric acid were not significantly altered, and the relative supersaturation for
struvite and brushite was decreased but did not reach statistical significance. The
increased oxalic acid excretion was proposed to be caused by the oxalic acid content
in cranberry juice (167 µmol/L oxalic acid). The authors concluded that since cranberry
juice lowers the pH of urine, it could be useful for the treatment of apatite, brushite,
and struvite stones as well as urinary tract infections; however, more research is
needed in patients with a history of kidney stones [82].
Patients with a history of struvite stones who consumed 2 pints of cranberry juice
per day for 9 y had no recurrence of stones (60% of patients), no increase of stone
size (32%), and no new stones or an increase in stone size (6%); however, the study
did not include a control group [17], [83].
Health Canada monographs have the following caution statement for the intake of cranberry
in individuals with a history of kidney stones: “Consult a health care practitioner/health
care provider/health care professional/doctor/physician before use if you have a history
of kidney stones” [43], [44]. The 2011 ANSES opinion concluded that “…given the data showing increased urinary
excretion of calcium oxalate, long-term consumption of cranberry in individuals prone
to oxalate kidney stones is not recommended” [47]. The ESCOP monograph on cranberry recommends that patients with a history of calcium
oxalate stone formation should seek medical advice before taking cranberry [48].
No AERs suggesting kidney stone formation associated with cranberry products were
found in searches of publicly available databases including the FDA CAERS [69] and the Canada Vigilance Program database [70].
Potential Drug Interactions with Cranberry
Potential Drug Interactions with Cranberry
Cases of cranberry interactions with warfarin were found in the literature search
for cranberry and drug interactions. Available clinical data and case reports suggest
that high intakes of cranberry juice (approximately 1 – 2 L) or cranberry extracts
(3000 mg/day) could potentially interfere with warfarin. However, moderate intakes
of cranberry juice (240 to 480 mL) in clinical studies did not exhibit interactions
with warfarin. Cases of elevated INR have been reported in patients taking cranberry
and warfarin [84], [85], [86]. One review evaluated 6 published case reports and 9 unpublished reports received
by the United Kingdom Committee of the Safety of Medicine. Of the 15 reports on cranberry
juice-warfarin interactions, only 2 had a “probable” interaction. The remaining reports
had a “possible” interaction score. In these cases, many of the patients had a serious
illness, were taking
concomitant medications, had dietary changes, and/or were consuming excessive
amounts of cranberry juice. The 2 “probable” cases were questionable since one case
involved a patient who was taking antibiotics and consuming high volumes of cranberry
juice (2 L daily) and the other case involved a patient who had stopped consuming
cranberry juice 2 days before showing an elevated INR [86].
No clinically relevant interactions were found in a review of 7 randomized clinical
studies that evaluated interactions between cranberry juice and warfarin or surrogate
drugs metabolized by the same isoenzymes as warfarin [86]. Other published reviews reported that the available evidence does not indicate
clinically relevant interactions between cranberry juice and warfarin [85], [86]. One clinical study reported that 250 mL of cranberry juice given to male patients
on warfarin therapy did not affect prothrombin time or INR (n = 7) [18]. Another study reported no statistical difference between mean prothrombin and baseline
in men taking stable doses of warfarin and consuming 240 mL cranberry juice twice
daily for 7 days (n = 10) [87]. Clinical trials did not identify an interaction between cranberry juice and cytochrome
P450 (CYP)
2C9 and 3A4 enzymes, both of which are required in warfarin metabolism [85]. One clinical study reported that an intake of 8 oz (240 mL) of cranberry juice
did not affect CYP2C9 activity in 14 healthy participants given the analgesic drug
flurbiprofen, which is a substrate for CYP2C9 [88]. A clinical study of 12 healthy male volunteers found that consuming 240 mL of cranberry
juice had no effect on the metabolism of cyclosporine, which is a substrate for CYP3A4
[89].
Notably, these clinical studies evaluated moderate intakes of cranberry juice (approximately
8 to 16 oz or 240 to 480 mL), whereas some of the case reports describing warfarin
interactions involved higher intakes. Other reviews of the available data and case
reports suggest that intakes of large volumes of cranberry juice (approximately 1 – 2 L
daily) may affect warfarin therapy. In contrast, smaller amounts of cranberry juice
are not expected to cause drug interactions [84], [90]. Cranberry juice concentrates in supplements may affect warfarin when taken for
extended periods (more than 3 – 4 wk) [90]. One clinical study evaluated the interaction potential between warfarin (25 mg/day)
and 1000 mg of concentrated cranberry extract tablets taken 3 times daily (3000 mg/day)
in healthy participants (n = 12). The authors reported that the cranberry extract
had increased the area under the
INR-time curve by approximately 30% when it was administered with warfarin compared
to warfarin treatment alone, a statistically and clinically significant difference.
The pharmacokinetics and plasma protein binding of S- or R-warfarin were not altered by cranberry extract. The authors concluded that cranberry
extract can affect warfarin pharmacodynamics with the potential to increase its effects,
but without altering its pharmacokinetics [91]. However, the equivalence between cranberry juice and cranberry extracts has not
been well established. The study used an equivalent of 57 g (4 tablespoons) of dry
cranberry daily, but data comparing the equivalence between dry cranberry and cranberry
juice are not available [86].
Regulatory bodies in other countries have provided cautions for cranberry concerning
the potential for drug interactions. Health Canada monographs for cranberry and dried
cranberry juice include the following caution statement for the intake of cranberry
in individuals taking blood thinners: “Consult a health care practitioner/health care
provider/health care professional/doctor/physician prior to use if you are taking
blood thinners” [43], [44]. The ANSES opinion noted that published reviews and studies reported no risk of
warfarin interactions with moderate cranberry juice intakes. However, ANSES noted
that risk at higher intake levels (> 600 mL/day) cannot be overlooked [47]. The ESCOP monograph on cranberry has also noted that interaction between cranberry
juice and warfarin is unlikely, especially for moderate intakes of cranberry [48].
Published reviews on cranberry note that no significant drug interactions with cranberry
have been reported [78] and that the potential for clinically important interactions is low [92]. The AHPA Botanical Safety Handbook classifies cranberry as Interaction Class A (i.e., an herb for which no clinically
relevant interactions are expected) [17]. Blood thinner drug product inserts specifically warn about interaction risks associated
with other drugs and botanical products. The prescribing information for Coumadin
(warfarin sodium) advises patients not to take botanical (herbal) supplement products
except on the advice of a health care provider. Cranberry was not explicitly listed
in the available prescribing information for Coumadin [93].
A total of 7 AERs reported to Health Canada [70] and the Australian TGA DAEN [71] involved changes in INR or coagulation parameters in consumers ingesting cranberry
juice or products containing cranberry-derived ingredients while taking prescription
blood thinners. However, these AERs involved the use of multi-ingredient products
and/or the concomitant intake of other products or medications, and causality could
not be determined.
Conclusion
The purpose of this review was to determine if any relevant safety concerns would
prevent the admission of cranberry to the USP monograph development process. The USP
DSAE JS3 considered all the available data and concluded that there was no serious
risk to human health associated with the use of DSs containing cranberry when used
at the recommended intake levels in products currently on the market. Clinical data
indicate no serious adverse effects were associated with the ingestion of cranberry
juice or juice concentrates and other cranberry preparations such as tablets or capsules.
The most common AEs were GI complaints. Low compliance and high withdrawal rates attributed
to palatability or GI complaints were mainly associated with cranberry juice. The
use of encapsulated cranberry preparations is suggested to offset the low compliance
that is observed for cranberry juice [24]. The small number of reported AEs relative to the widespread
consumption of cranberry juice indicates a low risk of adverse effects for cranberry
[17].
This review found that drug-herbal interactions with warfarin and kidney stone formation
were identified as potential risks to human health, and these safety concerns were
assessed by the USP DSAE JS3. Available data indicate no risk of warfarin interactions
with moderate intakes of cranberry juice, although higher intakes cannot be overlooked
[47]. Moderate intakes of cranberry juice have not exhibited interactions with warfarin,
but ingestion of large amounts of cranberry juice (approximately 1 – 2 L) or cranberry
extract (3000 mg/day) could potentially interfere with warfarin [84], [85], [86], [91]. DS products have recommended intakes of less than 1350 mg/day of cranberry extract,
which suggests that cranberry extracts less than this amount are not likely to cause
adverse interactions. No evidence of clinically relevant
interactions between cranberry juice and warfarin has been reported [85], [86].
Human studies have shown contradictory data regarding the role of cranberry in kidney
stone formation [17]. Some clinical studies have indicated that individuals with a history of developing
uric acid or calcium oxalate stones are at risk when consuming cranberry products
[75], while other studies have reported that consumption of large amounts of cranberry
may reduce kidney stone formation or reduce urinary ionized calcium associated with
stone formation [51], [76], [77]. There is insufficient data to suggest kidney stone formation is associated with
intakes of cranberry [80].
Based on the safety review conducted, the following cranberry ingredient monographs
were admitted to the USP monograph development process: Cranberry Fruit Juice, Cranberry
Fruit Juice Concentrate, Cranberry Fruit Juice Dry Extract, and Cranberry Fruit Dry
Juice. Limited safety information is available on cranberry use during pregnancy or
lactation, but traditional consumption of cranberry suggests no adverse effects [17]. However, because of limited safety data on their use by pregnant or breastfeeding
women, cranberry DS products claiming compliance with USP standards will be expected
to comply with the USP–NF General Chapter <7> Labeling, which states that the label of an herb or other botanical intended for use as a
DS shall bear the following statement: “If you are pregnant or nursing a baby, seek
the advice of a health professional before using this product”. Based on the available
data, the USP DSAE JS3 concluded that
cautionary labeling statements regarding the use of cranberry ingredients for
individuals on blood thinners or those at risk for kidney stone formation are not
necessary for quality standards pertaining to cranberry ingredients in DS products.
Recommendations can be made for further research to clarify some of the uncertainties
associated with cranberry based on the literature that was assessed in this review.
More studies are required to further clarify the role between cranberry and kidney
stone formation. Because clinical studies have evaluated variable cranberry preparations
with often limited to no detail on their chemical profiles, studies with better experimental
designs are needed along with a clear identification of the bioactive constituents
present in the cranberry preparations being studied. Preclinical studies on the safety
of cranberry and its constituents were found to be generally lacking. Further in vitro and in vivo toxicology studies are recommended to provide more safety information on cranberry
preparations and their constituents.
Contributorsʼ Statement
Data collection: E. Madden, C. McLachlan, A. I. Calderon. Analysis and interpretation
of the data: E. Madden, C. McLachlan, A. I. Calderon. Drafting the manuscript: E.
Madden, C. McLachlan. Critical revision of the manuscript: E. Madden, H. Oketch-Rabah,
A. I. Calderon.
